Substance P involved in mental disorders.
1. This review clarifies the involvement of substance P (SP) in mental disorders, especially schizophrenia. One of the main SP pathways in the brain is the striatonigral pathway. SP applied in the substantia nigra activates the nigro-striatal dopamine system. 2. Administration of antipsychotic drugs decreased SP concentration in the substantia nigra. Some post mortem studies of schizophrenic patients showed elevated SP concentration in some brain regions. Effects of baclofen, a SP antagonist, on schizophrenic patients are uncertain. 3. SP may be involved in the pathophysiology of schizophrenia.
Takeuchi
K
K
Department of Neurology and Psychiatry, Gifu University School of Medicine, Japan.
Uematsu
M
M
Ofuji
M
M
Morikiyo
M
M
Kaiya
H
H
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D001523:Mental Disorders / Q000503:physiopathology*; D012559:Schizophrenia / Q000503:physiopathology*; D013373:Substance P / Q000502:physiology*
D014150:Antipsychotic Agents; D013373:Substance P